The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Open accessAbstract
A main limitation of therapies that selectively target kinase signalling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of epidermal growth factor receptor (EGFR), is effective in a subset of KRAS wild-type metastatic colorectal cancers. After an initial response, secondary resistance invariably ensues, thereby limiting the clinical benefit of this drug. The molecular bases of secondary resistance to cetuximab in colorectal cancer are poorly understood. Here we show that molecular alterations (in most instances point mutations) of KRAS are causally associated with the onset of acquired resistance to anti-EGFR treatment in colorectal cancers. Expression of mutant KRAS under the control of its endogenous gene promoter was sufficient to confer cetuximab resistance, but resistant cells remained sensitive to combinatorial inhibition of EGFR and mitogen-activated protein-kinase kinase (MEK). Analysis of metastases from patients who developed resistance to cetuximab or panitumumab showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% (6 out of 10) of the cases. KRAS mutant alleles were detectable in the blood of cetuximab-treated patients as early as 10 months before radiographic documentation of disease progression. In summary, the results identify KRAS mutations as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who initially respond to anti-EGFR develop acquired resistance within 12 to 18 months due to secondary mutations in KRAS genes, EGFR exodomain alteration, and clonal selection [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We and others previously reported that KRAS acquired mutations are responsible for secondary resistance to anti-EGFR therapies in CRC(22, 23).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Patients who fail to respond to therapy initially exhibit intrinsic resistance, whereas those who relapse after initial response are associated with acquired resistance [9].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [9]
In the citing paper
“Emergence of KRAS amplification and acquisition of secondary KRAS mutations (G12C, G12D, G13D and Q61H) was detected as one mechanism of acquired resistance in metastatic CRC patients, who relapsed on cetuximab or panitumumab treatment (78, 79).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [78]
In the citing paper
“KRAS point mutations and gene copy number gains are responsible not only for primary but also for acquired resistance in 38–60 % of patients who relapse on cetuximab or panitumumab [37-39].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“KRAS alterations could be identified noninvasively 5–10 months before radiographic disease progression by analyzing cell-free circulating tumor DNA (ctDNA) [37, 38].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“however, the proof of principle that such an approach could complement tumor biopsy and provide an early warning of acquired resistance has been established [38, 41, 136].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [38]
In the citing paper
“To address these challenges, Mirati Therapeutics conducted high-resolution crystal structure analyses of compounds bound to mutant KRAS proteins, optimizing these compounds to develop MRTX1133, a non-covalent, selective inhibitor for KRAS G12D [60].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [60]
In the citing paper
“For instance, BRAF (V600E) and MAP2K1/MEK1 (K57T, K57N, I99_K104 deletion, and E102_I103 deletion) can also cause acquired drug resistance [94, 108–111].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [110]
In the citing paper
“By performing repeat biopsies and evaluating circulating tumor DNA, investigators observed the emergence of KRAS mutations as a resistance mechanism (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
In the citing paper
“non-invasive measures such as molecular interrogation of circulating tumor cells or plasma DNA may help capture the heterogeneity of resistance in patients, as was done to identify the development of KRAS mutations in colorectal cancers that acquire resistance to cetuximab (Diaz et al., 2012; Misale et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Misale et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Self-citationMolecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Self-citationActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Flagged first, then by citations
2 of the 25 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,014
Kim, S. T., Banks, K. C., Lee, S., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 72
Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers
Quinchía, J., Echeverri, D., Cruz‐Pacheco, A. F., Celis, M. E. M., & Orozco, J. (2020) · Micromachines · doi:10.3390/mi11040411 · Cited by 72
Onstenk, W., Gratama, J. W., Foekens, J. A., & Sleijfer, S. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.001 · Cited by 72
Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons
Tan, C. R. C., Zhou, L., & El‐Deiry, W. S. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0320-y · Cited by 72
Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment
Song, C., Liu, Y., Fontana, R. E., Makrigiorgos, A., Mamon, H. J., Kulke, M. H., & Makrigiorgos, G. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw650 · Cited by 72
Vakana, E., Pratt, S. E., Blosser, W. D., Dowless, M. S., Simpson, N., Yuan, X., Jaken, S., Manro, J. R., Stephens, J. R., Zhang, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14002 · Cited by 72
Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
Coyle, K. M., Boudreau, J. E., & Marcato, P. (2017) · BioMed Research International · doi:10.1155/2017/9620870 · Cited by 72
Radiomics and liquid biopsy in oncology: the holons of systems medicine
Neri, E., Re, M. D., Paiar, F., Erba, P. A., Cocuzza, P., Regge, D., & Danesi, R. (2018) · Insights into Imaging · doi:10.1007/s13244-018-0657-7 · Cited by 72
Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Puliafito, A., Lamba, S., Erriquez, J., Bertotti, A., Gherardi, M., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01105-z · Cited by 71
Self-citationNon‐invasive detection of genome‐wide somatic copy number alterations by liquid biopsies
Heitzer, E., Ulz, P., Geigl, J. B., & Speicher, M. R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.004 · Cited by 71
MicroRNAs in cancer drug resistance: Basic evidence and clinical applications
Ghasabi, M., Mansoori, B., Mohammadi, A., Duijf, P. H. G., Shomali, N., Shirafkan, N., Mokhtarzadeh, A., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26810 · Cited by 71
Wong, N. A. C. S., de Castro, D. G., Salto‐Tellez, M., Butler, R., Díaz‐Cano, S. J., Ilyas, M., Newman, W. G., Shaw, E. C., Tanière, P., & Walsh, S. V. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202467 · Cited by 70
Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer
Roy, M., & Finley, S. D. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00217 · Cited by 70
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 70
EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation
Wang, M., Kern, A. M., Hülskötter, M., Greninger, P., Singh, A., Pan, Y., Chowdhury, D., Krause, M., Baumann, M. A., Benes, C. H., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3157 · Cited by 70
Khan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 70
Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer
Cheng, J., Li, Y., Wang, X., Dong, G., & Sheng, C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00929 · Cited by 69
Zhang, Y. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000906 · Cited by 69
Garrido‐Laguna, I., McGregor, K., Wade, M. L., Weis, J. R., Gilcrease, W., Burr, L., Soldi, R., Jakubowski, L., Davidson, C., Morrell, G., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9947-6 · Cited by 69
Takegawa, N., Yonesaka, K., Sakai, K., Ueda, H., Watanabe, S., Nonagase, Y., Okuno, T., Takeda, M., Maenishi, O., Tsurutani, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6498 · Cited by 69
Desir, S., Wong, P., Turbyville, T. J., Chen, D., Shetty, M., Clark, C., Zhai, E., Romin, Y., Manova-Todorova, K. O., Starr, T. K., et al. (2019) · Cancers · doi:10.3390/cancers11070892 · Cited by 69
ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
Jaiswal, B. S., Durinck, S., Stawiski, E. W., Yin, J., Wang, W., Lin, E., Moffat, J. G., Martin, S. E., Modrusan, Z. D., & Seshagiri, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3674 · Cited by 69
Sánchez-Martín, F. J., Bellosillo, B., Gelabert-Baldrich, M., Dalmases, A., Cañadas, I., Vidal, J., Martinez, A., Argilés, G., Siravegna, G., Arena, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2400 · Cited by 68
Self-citationCirculating tumor cell profiling for precision oncology
Labib, M., & Kelley, S. O. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12901 · Cited by 68
Wong, A. L. A., Lim, J. S. J., Sinha, A. K., Gopinathan, A., Lim, R. S. C., Tan, C., Soh, I., Venkatesh, S. K., Titin, C., Sapari, N. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0405-4 · Cited by 68
Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities
Normanno, N., Rachiglio, A. M., Roma, C., Fenizia, F., Esposito, C., Pasquale, R., Porta, M. L. L., Iannaccone, A., Micheli, F., Santangelo, M. L., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24401 · Cited by 68
MicroRNAs are important regulators of drug resistance in colorectal cancer
Zhang, Y., & Wang, J. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0308 · Cited by 68
A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
Liao, S., Davoli, T., Leng, Y., Li, M. Z., Xu, Q., & Elledge, S. J. (2017) · Genes & Development · doi:10.1101/gad.291948.116 · Cited by 67
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
Shitara, K., Yonesaka, K., Denda, T., Yamazaki, K., Moriwaki, T., Tsuda, M., Takano, T., Okuda, H., Nishina, T., Sakai, K., et al. (2016) · Cancer Science · doi:10.1111/cas.13098 · Cited by 67
Clinical application of circulating tumour DNA in colorectal cancer
Loft, M., To, Y. H., Gibbs, P., & Tie, J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00146-2 · Cited by 67
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., Grob, T. J., Alawi, M., Indenbirken, D., Kriegs, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3574 · Cited by 67
Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach
Blanco, M., Concha, Á., Figueroa, A., Garrido, F., & Valladares‐Ayerbes, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160613610 · Cited by 67
In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Rosa, R., Monteleone, F., Zambrano, N., & Bianco, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113209990226 · Cited by 67
Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 66
Stein, A., Simnica, D., Schultheiß, C., Scholz, R., Tintelnot, J., Goekkurt, E., von Wenserski, L., Willscher, E., Paschold, L., Sauer, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002844 · Cited by 66
Current and Developing Liquid Biopsy Techniques for Breast Cancer
Wu, H., & Chu, P. (2022) · Cancers · doi:10.3390/cancers14092052 · Cited by 66
Boccaccio, C., & Comoglio, P. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4039 · Cited by 66
Lee, J., Om, J.-Y., Kim, Y., Kim, K., Choi, E. H., & Kim, K.-N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150279 · Cited by 66
Liquid biopsy of gastric cancer patients: Circulating tumor cells and cell-free nucleic acids
Tsujiura, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i12.3265 · Cited by 65
Li, C., Ho, M., Lin, Y., Tzeng, S., Chen, Y., Pai, H., Wang, Y.-C., Chen, C., Lee, Y., Chen, D., et al. (2020) · Hepatology · doi:10.1002/hep.31230 · Cited by 67
Self-citationLee, Y., Lee, G. K., Lee, Y., Zhang, W., Hwang, J., Nam, B., Kim, S. H., Joo‐Hang, K. I. M., Yun, T., Han, J., et al. (2014) · Cancer · doi:10.1002/cncr.28711 · Cited by 64
Ray, K., Újvári, B., Ramana, V., & Donald, J. A. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.002 · Cited by 64
Gao, X., Qiao, X., Xing, X., Huang, J., Qian, J., Wang, Y., Zhang, Y., Zhang, X., Li, M., Cui, J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01563 · Cited by 64
The translational potential of circulating tumour DNA in oncology
Patel, K., & Tsui, D. W. Y. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.04.005 · Cited by 64
Nanotechnologies for the treatment of colon cancer: From old drugs to new hope
Kotelevets, L., Chastre, E., Desmaële, D., & Couvreur, P. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.06.005 · Cited by 64
Hecht, J. R., Douillard, J., Schwartzberg, L. S., Grothey, A., Kopetz, S., Rong, A., Oliner, K. S., & Sidhu, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.008 · Cited by 63
Roth, B. J., Krilov, L., Adams, S., Aghajanian, C. A., Bach, P. B., Braiteh, F., Brose, M. S., Ellis, L. M., Erba, H. P., George, D. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1938 · Cited by 63
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Palacín-Aliana, I., Garcia‐Romero, N., Asensi-Puig, A., Carrión-Navarro, J., González‐Rumayor, V., & Ayuso‐Sacido, Á. (2021) · Biomedicines · doi:10.3390/biomedicines9080906 · Cited by 63
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor
Orzan, F., Bacco, F. D., Crisafulli, G., Pellegatta, S., Mussolin, B., Siravegna, G., D’Ambrosio, A., Comoglio, P. M., Finocchiaro, G., & Boccaccio, C. (2017) · Stem Cells · doi:10.1002/stem.2703 · Cited by 63
Self-citationKRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., de Castro, D. G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19212-5 · Cited by 63
P5 eHealth: An Agenda for the Health Technologies of the Future
Pravettoni, G., & Triberti, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-27994-3 · Cited by 63
Expanded RAS: Refining the Patient Population
Atreya, C. E., Corcoran, R. B., & Kopetz, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9325 · Cited by 63
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
Jankú, F., Vibat, C. R. T., Kosco, K. A., Holley, V. R., Cabrilo, G., Meric‐Bernstam, F., Stepanek, V. M. T., Lin, P. P., Leppin, L., Hassaine, L., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1964 · Cited by 62
The role of epigenetic therapies in colorectal cancer
Baretti, M., & Azad, N. S. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.03.001 · Cited by 62
Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes
Feeney, L., Harley, I. J. G., McCluggage, W. G., Mullan, P. B., & Beirne, J. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i11.868 · Cited by 62
Tumour heterogeneity and evolutionary dynamics in colorectal cancer
Chan, D. K. H., & Buczacki, S. J. A. (2021) · Oncogenesis · doi:10.1038/s41389-021-00342-x · Cited by 62
Nakamura, Y., Fujisawa, T., Taniguchi, H., Bando, H., Okamoto, W., Tsuchihara, K., Yoshino, T., & Ohtsu, A. (2021) · Cancer Science · doi:10.1111/cas.15132 · Cited by 62
The clinical relevance of KRAS gene mutation in non-small-cell lung cancer
Tı́már, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000051 · Cited by 62
Allin, D., Shaikh, R., Carter, P., Thway, K., Sharabiani, M. T. A., de Castro, D. G., O’Leary, B., García-Murillas, I., Bhide, S. A., Hubank, M. J. F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.013 · Cited by 62
Historical perspective: Two decades of progress in treating metastatic colorectal cancer
Lee, R. M., Cardona, K., & Russell, M. C. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25431 · Cited by 62
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Liquid biopsy in pancreatic cancer: the beginning of a new era
Yadav, D. K., Bai, X., Yadav, R. K., Singh, A., Li, G., Ma, T., Chen, W., & Liang, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24809 · Cited by 62
Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis
Breuer, E., Hebeisen, M., Schneider, M. A., Roth, L., Pauli, C., Frischer-Ordu, K., Eden, J., Pache, B. C.-E., Steffen, T., Hübner, M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab001 · Cited by 61
Benhaïm, L., Bouché, O., Normand, C., Didelot, A., Mulot, C., Corre, D. L., Garrigou, S., Djadi‐Prat, J., Renault, S., Perez‐Toralla, K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.004 · Cited by 61
Markers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib, W. L., Mahajan, R., & El‐Rayes, B. F. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.029 · Cited by 61
Krebs, M., Renehan, A. G., Backen, A. C., Gollins, S., Chau, I., Hasan, J., Valle, J. W., Morris, K. L., Beech, J., Ashcroft, L., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.006 · Cited by 61
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
Nigro, C. L., Ricci, V., Vivenza, D., Granetto, C., Fabozzi, T., Miraglio, E., & Merlano, M. C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6944 · Cited by 61
Moghaddam, L. K., Paschepari, S. R., Zaimy, M. A., Abdalaian, A., & Jebali, A. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.38 · Cited by 61
Ng, S. B. H., Chua, C., Ng, M. C. H., Gan, A., Poon, P. S. Y., Teo, M. C. C., Fu, C. W. P., Leow, W. Q., Lim, K. H., Chung, A. Y. F., et al. (2017) · Scientific Reports · doi:10.1038/srep40737 · Cited by 61
Sherwood, K. R., & Weimer, E. T. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.09.011 · Cited by 61
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 60
Lenkiewicz, E., Malasi, S., Hogenson, T. L., Flores, L. F., Barham, W. J., Phillips, W. J., Roesler, A. S., Chambers, K. R., Rajbhandari, N., Hayashi, A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0078 · Cited by 60
Assessment of DNA Integrity, Applications for Cancer Research
Zonta, E., Nizard, P., & Taly, V. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.03.002 · Cited by 60
Kin, C., Kidess, E., Poultsides, G. A., Visser, B. C., & Jeffrey, S. S. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.811896 · Cited by 60
Blood circulating tumor DNA for non‐invasive genotyping of colon cancer patients
Siravegna, G., & Bardelli, A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.005 · Cited by 60
Self-citationEnhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
Lee, T., Tseng, Y.-C., Nguyễn, P. A., Li, Y., Ho, C., & Wu, C.-W. (2018) · Scientific Reports · doi:10.1038/s41598-017-18527-z · Cited by 60
RNAactDrug: a comprehensive database of RNAs associated with drug sensitivity from multi-omics data
Dong, Q., Li, F., Xu, Y., Xiao, J., Xu, Y., Shang, D., Zhang, C., Yang, H., Tian, Z., Mi, K., et al. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz142 · Cited by 60
Perspectives of the Application of Liquid Biopsy in Colorectal Cancer
Ding, Y., Li, W., Wang, K., Xu, C., Hao, M., & Ding, L. (2020) · BioMed Research International · doi:10.1155/2020/6843180 · Cited by 61
Role of cMET in the Development and Progression of Colorectal Cancer
Pérez-Vargas, J. C. S., Biondani, P., Maggi, C., Gariboldi, M., Gloghini, A., Inno, A., Volpi, C. C., Gualeni, A. V., Bartolomeo, M. D., de Braud, F., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918056 · Cited by 59
Syn, N. L. X., Yong, W. P., Goh, B. C., & Lee, S. C. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1196187 · Cited by 59
Riediger, A. L., Dietz, S., Schirmer, U. B., Meister, M. A., Heinzmann-Groth, I., Schneider, M. A., Muley, T., Thomas, M., & Sültmann, H. (2016) · Scientific Reports · doi:10.1038/srep33505 · Cited by 59
Toledo, R. A., Cubillo, A., Vega, E., Garralda, E., Álvarez-Gallego, R., Varga, L. U. D. L., Rodríguez-Pascual, J., Sánchez, G., Sarno, F., Prieto, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13311 · Cited by 59
Characterization of background noise in capture-based targeted sequencing data
Park, G., Park, J. K., Shin, S., Jeon, H.-J., Kim, N. K. D., Kim, Y. J., Shin, H., Lee, E., Lee, K. H., Son, D., et al. (2017) · Genome biology · doi:10.1186/s13059-017-1275-2 · Cited by 60
Przybył, J., Chabon, J. J., Spans, L., Ganjoo, K. N., Vennam, S., Newman, A. M., Forgó, E., Varma, S., Zhu, S., Dêbiec‐Rychter, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3704 · Cited by 59
McDaid, W. J., Greene, M. K., Johnston, M. C., Pollheimer, E., Smyth, P., McLaughlin, K., Van Schaeybroeck, S., Straubinger, R. M., Longley, D. B., & Scott, C. J. (2019) · Nanoscale · doi:10.1039/c9nr07257h · Cited by 58
Patel, S. A., Rodrigues, P., Wesolowski, L., & Vanharanta, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01127-6 · Cited by 57
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58
Wiersma, V. R., de Bruyn, M., Wei, Y., van Ginkel, R. J., Hirashima, M., Niki, T., Nishi, N., Zhou, J., Pouwels, S. D., Samplonius, D. F., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1063767 · Cited by 58
Lupini, L., Bassi, C., Mlčochová, J., Musa, G., Russo, M., Vychytilova‐Faltejskova, P., Svoboda, M., Sabbioni, S., Němeček, R., Slabý, O., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1752-5 · Cited by 58
Dorbeau, M., Bazille, C., & Bibeau, F. (2017) · Côlon & Rectum · doi:10.1007/s11725-017-0702-6 · Cited by 58
Joosten, S. P. J., Zeilstra, J., van Andel, H., Mijnals, R. C. D., Zaunbrecher, J., Duivenvoorden, A. A. M., van de Wetering, M., Clevers, H. C., Spaargaren, M., & Pals, S. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.008 · Cited by 58
Nightingale, J., Lum, B., Ladwa, R., Simpson, F., & Panizza, B. J. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188523 · Cited by 58
Haley, L. M., Tseng, L., Zheng, G., Dudley, J. C., Anderson, D. A., Azad, N. S., Gocke, C. D., Eshleman, J. R., & Lin, M. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.86 · Cited by 57
Improving outcomes in colorectal cancer: Where do we go from here?
Cutsem, E. V., Borràs, J. M., Castells, A., Ciardiello, F., Ducreux, M. P., Haq, A., Schmoll, H., & Tabernero, J. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.026 · Cited by 57
BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition
de Farias, C. B., Heinen, T. E., dos Santos, R. P., Abujamra, A. L., Schwartsmann, G., & Roesler, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.091 · Cited by 57
Wykosky, J., Hu, J., Gomez, G. G., Taylor, T. E., Villa, G. R., Pizzo, D. P., VandenBerg, S. R., Thorne, A. H., Chen, C. C., Mischel, P. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2004 · Cited by 57
Self-citationPolívka, J., Pešta, M., & Jankú, F. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1110021 · Cited by 57
Nam, S. K., Yun, S., Koh, J., Kwak, Y., Seo, A. N., Park, K. U., Kim, D., Kang, S., Kim, W. H., & Lee, H. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151865 · Cited by 57
Metadata
- Authors
- Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.-T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Solit, David
- Bardelli, Alberto
- ORCID
- Venue
- Nature
- Published
- 2012-06
- Volume
- 486
- Issue
- 7404
- Pages
- 532-536
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3927413
- OpenAlex
- W2062109911
- Cited by
- 1,889
- References
- 25
- Citations by year
- 2026: 75 · 2025: 73 · 2024: 81 · 2023: 115 · 2022: 129 · 2021: 138 · 2020: 134 · 2019: 163 · 2018: 161 · 2017: 171 · 2016: 177 · 2015: 163 · 2014: 145 · 2013: 133 · 2012: 28
- FWCI
- 73.66
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Memorial Sloan-Kettering Cancer Center
- European Commission (259015)
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- National Cancer Institute (R01CA127240, P30CA008748, T32CA009207, R25CA020449)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS mutation, acquired drug resistance, anti-EGFR therapy, cetuximab resistance, colorectal cancer, EGFR, K-ras oncogene, circulating tumor DNA, tumor subclones, MEK inhibition, combination therapy, metastatic colorectal cancer, tumor heterogeneity
- MeSH terms
- Cetuximab, Panitumumab, Alleles, Antibodies, Monoclonal, Humans, Mutation, Promoter Regions, Genetic, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
